Literature DB >> 22023636

The potential therapeutic use of stem cells in cartilage repair.

Jonathan R Perera1, Parag K Jaiswal, Wasim S Khan.   

Abstract

As our population demographics change, osteoarthritis and cartilage defects are becoming more prevalent. The discovery of stems cells and their ability for indefinite regeneration has revolutionised the way cartilage problems are viewed. Tissue engineering has been shown to be the ideal way of repairing articular cartilage lesions, i.e. back to native tissue. Cartilage is an ideal tissue engineering target as it is avascular, aneural and alymphatic. The two main types of stem cells being investigated in chondrogenesis are embryological and mesenchymal stem cells. Research into embryological stem cells has been surrounded by controversy because of ethical, religious and social concerns. We discuss the use of embryological and mesenchymal stem cells in cartilage repair and the various factors involved in the differentiation into chondrocytes. We also discuss commonly used mesenchymal stem cell markers and their limitations.

Entities:  

Mesh:

Year:  2012        PMID: 22023636     DOI: 10.2174/157488812799219054

Source DB:  PubMed          Journal:  Curr Stem Cell Res Ther        ISSN: 1574-888X            Impact factor:   3.828


  3 in total

1.  Can notochordal cells promote bone marrow stromal cell potential for nucleus pulposus enrichment? A simplified in vitro system.

Authors:  Esther Potier; Keita Ito
Journal:  Tissue Eng Part A       Date:  2014-12       Impact factor: 3.845

2.  The potential of stem cells in the treatment of skeletal muscle injury and disease.

Authors:  S Maclean; W S Khan; A A Malik; S Anand; M Snow
Journal:  Stem Cells Int       Date:  2011-12-19       Impact factor: 5.443

3.  Type II collagen and glycosaminoglycan expression induction in primary human chondrocyte by TGF-β1.

Authors:  Hyun Joo Yoon; Suk Bum Kim; Dhara Somaiya; Moon Jong Noh; Kyoung-Baek Choi; Chae-Lyul Lim; Hyeon-Youl Lee; Yeon-Ju Lee; Youngsuk Yi; Kwan Hee Lee
Journal:  BMC Musculoskelet Disord       Date:  2015-06-10       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.